Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Improving efficiency of phase III trials is paramount for reducing costs, hastening approvals, and mitigating exposure to disadvantageous randomizations. Compared to standard frequentist interim analysis, Bayesian early stopping rules may improve efficiency by the flexibility of differential priors for efficacy and futility coupled with evaluation of clinically meaningful effect sizes.
Methods: Individual patient-level data from 184,752 participants across 230 randomized two-arm parallel oncology phase III trials were manually reconstructed from primary endpoint Kaplan-Meier curves. Accrual dynamics, but not patient outcomes, were randomly varied. Bayesian Cohen's κ assessed agreement between the original analysis and the Bayesian interim analysis.
Results: Trial-level early closure was recommended based on the Bayesian interim analysis for 82 trials (36%), including 62 trials which had performed frequentist interim analysis and 33 which were already closed early by the frequentist interim analysis. Bayesian early stopping rules were 96% sensitive for detecting trials with a primary endpoint difference, and there was a high level of agreement in overall trial interpretation (κ, 0.95). Moreover, Bayesian interim analysis was associated with reduced enrollment.
Conclusions: Bayesian interim analyses seem to improve trial efficiency by reducing enrollment requirements without compromising interpretation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41416-025-03156-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: WU-KONG1B (ClinicalTrials.gov identifier: NCT03974022) is a multinational phase II, dose-randomized study to assess the antitumor efficacy of sunvozertinib in pretreated patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor () exon 20 insertion mutations (exon20ins).
Methods: Eligible patients with advanced-stage exon20ins NSCLC were randomly assigned by 1:1 ratio to receive sunvozertinib 200 mg or 300 mg once daily (200 and 300 mg-rand cohorts).
Vortioxetine for Major Depressive Disorder in Children: 12-Week Randomized, Placebo-Controlled Study.
JAACAP Open
September 2025
H. Lundbeck A/S, Copenhagen, Denmark.
Objective: To evaluate efficacy, safety, and tolerability of vortioxetine in children ages 7 to 11 years with major depressive disorder.
Method: Patients meeting criteria for incomplete improvement in depressive symptoms (Children's Depression Rating Scale-Revised [CDRS-R] total score ≥40 plus <40% reduction and Parent Global Assessment Global Improvement score >2) after 4 weeks of single-blind lead-in treatment with a brief psychosocial intervention plus placebo were randomized 1:1:1:1 to 8-week double-blind treatment with brief psychosocial intervention and placebo, vortioxetine 10 mg/day, vortioxetine 20 mg/day, or fluoxetine 20 mg/day. Following preplanned interim analysis, enrollment to fluoxetine was stopped, and patients were randomized 1:1:1 to placebo, vortioxetine 10 mg, or vortioxetine 20 mg.
Effects of intravenous laser irradiation on viral load and T lymphocytes in people living with HIV/AIDS.
Rev Esc Enferm USP
September 2025
Universidade Estadual Paulista, Faculdade de Medicina, Botucatu, SP, Brazil.
Objective: To evaluate the effectiveness of intravenous laser irradiation of blood in reducing viral load and increasing LT-CD4+ and LT-CD8+ in people living with HIV/AIDS.
Method: Randomized, controlled, parallel, single-blind clinical trial. Twenty-eight participants were allocated to the intervention (ILIB n = 15) and control (CTRL n = 13) groups.
Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis.
Biologics
August 2025
Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
Objective: We aim to evaluate the malignancy risk between Janus kinase inhibitors (JAKi) users and tumor necrosis factor inhibitors (TNFi) users in rheumatoid arthritis (RA) patients, using a large real-world electronic health record database (TriNetX).
Methods: In this retrospective cohort study, we identified adult RA patients initiating JAKi or TNFi therapy between January 1, 2018, and December 31, 2022, within the TriNetX global federated network. The hazard ratio (HR) and confidence intervals (CI) of incident-specific cancers, overall cancer incidence, and all-cause mortality, were calculated between the propensity score matched JAKi and TNFi cohorts.
Explainable Machine Learning Assists in Revealing Associations Between Polysomnographic Biomarkers and Incident Type 2 Diabetes in Men.
Nat Sci Sleep
August 2025
Flinders Health and Medical Research Institute-- Sleep Health (Adelaide Institute for Sleep Health), College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia.
Introduction: Type 2 diabetes (T2D) shows bidirectional relationships with polysomnographic measures. However, no studies have searched systematically for novel polysomnographic biomarkers of T2D. We therefore investigated if state-of-the-art explainable machine learning (ML) models could identify new polysomnographic biomarkers predictive of incident T2D.
View Article and Find Full Text PDF